[Symposium for Health Technology Assessment: patients in no-man's-land].
Göhlen
Britta
B
Deutsche Agentur für HTA des DIMDI (DAHTA), Köln.
Borowski
Sven
S
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020811:Biomedical Technology / Q000379:methods*; D002908:Chronic Disease / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D005858:Germany / Q000453:epidemiology; D006801:Humans; D039441:Integrin alpha4 / Q000191:economics / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000191:economics; D000069442:Natalizumab; D020380:Needs Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4